DUBLIN, June 2, 2023 /PRNewswire/ — The “Global Microbiome Partnering Terms and Agreements 2010 to 2023” report has been added to ResearchAndMarkets.com’s offering. This report provides an understanding and access to the microbiome partnering deals and agreements entered into by the world’s leading healthcare companies. Trends in microbiome partnering deals Disclosed headlines, upfronts, milestones and … Read more
SILVER SPRING, Md., June 2, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA provided an update on medical device reports it received that are reportedly associated with the breakdown or suspected breakdown of the polyester-based polyurethane (PE-PUR) foam used … Read more
MEXICO CITY, June 2, 2023 /PRNewswire/ — Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a … Read more
Six médicaments développés par Dragonfly sont actuellement en clinique. WALTHAM, Massachusetts, 2 juin 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., a annoncé aujourd’hui avoir élargi son équipe de direction clinique en y intégrant le Dr Robin Edwards, anciennement directeur mondial des sciences translationnelles chez Daiichi Sankyo et directeur des sciences translationnelles chez Bristol Myers Squibb, et … Read more
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall … Read more
DUBLIN, June 1, 2023 /PRNewswire/ — The “Peptide Therapeutics Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global peptide therapeutics market grew from $37.26 billion in 2022 to $40.7 billion in 2023 at a … Read more
PHILADELPHIA, June 1, 2023 /PRNewswire/ — Kang Haggerty LLC announced today that they obtained a $9 Million settlement in a non-intervened fentanyl false claims act qui tam case against private equity firm Belhealth Investment Partners, its principals, Harold Blue, Inder Tallur, and Dennis Drislane, and its pharmacy portfolio companies, Linden Care and Quick Care. The … Read more
LUND, Sweden, June 1, 2023 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained reimbursement in Belgium for its first-in-class treatment, Idefirix, for the desensitization treatment of highly sensitized adult patients prior to kidney transplant from a deceased donor. Idefirix is available … Read more
BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, May 31, 2023 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with … Read more
DUBLIN, May 31, 2023 /PRNewswire/ — The “Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030” report has been added to ResearchAndMarkets.com’s offering. The global HIV treatment market in 2022 stood at US$22.38 billion, and is likely to reach US$25.49 billion by 2030. … Read more